The FDA approved Zerbaxa June 3 for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Zerbaxa, a combination of cephalosporin ceftolozane and tazobactam, was initially approved in 2014 to treat intra-abdominal infections and complicated urinary tract infections.
The new indication for the drug, given by injection, was demonstrated in a double-blind study that compared the drug to another antibacterial drug. Mortality and cure rates for Zerbaxa were similar to the treatment used as a comparison.
Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia are life-threatening pulmonary infections that often affect already vulnerable patients. They are also the second most common type of hospital-acquired infection in the U.S.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Zerbaxa is manufactured by Merck.
Date: June 10, 2019
Source: Beckers Hospital Review